BRAF V600E expression in ameloblastomas, ameloblastic carcinomas and cysts

doi:10.19439/j.sjos.2023.06.012

Abstract

Abstract: PURPOSE: To investigate protein and genetic status of BRAF V600E in ameloblastomas, ameloblastic carcinomas and cysts, and to explore if recurrence and malignant transformation of ameloblastomas depends on BRAF status. METHODS: Twenty cysts, 25 primary ameloblastomas, 25 recurrent ameloblastomas and 8 ameloblastic carcinomas were analysed by immunohistochemistry, and 2 cysts, 5 primary ameloblatomas, 5 recurrent ameloblastomas, 3 atypical ameloblastomas and 6 ameloblastic carcinomas were analysed by quantitative real-time PCR(qPCR). SPSS 26.0 software package was used for data analysis. RESULTS: There was no correlation between BRAF V600E expression and recurrence. Cysts and carcinomas had lower frequencies of BRAF V600E mutations than ameloblastomas. There was a concordance between positive staining of BRAF V600E protein and BRAF V600E mutation. CONCLUSIONS: BRAF V600E mutation may be useful in the differential diagnosis of ameloblastomas with cysts and ameloblastic carcinomas. Immunohistochemistry may be a beneficial method to screen for BRAF V600E mutation in ameloblastoma.

Key words: Ameloblastoma, Ameloblastic carcinoma, BRAF V600E, Recurrence

CLC Number:

R739.8

PEI Jing, ZHANG Lin, JIA Yun-xiang, CHEN Wei-hua. BRAF V600E expression in ameloblastomas, ameloblastic carcinomas and cysts[J]. Shanghai Journal of Stomatology, 2023, 32(6): 630-634.

References

[1] Brown NA, Rolland D, McHugh JB, et al. Activating FGFR2-RAS-BRAF mutations in ameloblastoma[J] Clin Cancer Res, 2014, 20(21): 5517-5526.
[2] Capper D, Preusser M, Habel A, et al.Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody[J]. Acta Neuropathol, 2011, 122(1): 11-19.
[3] Fernandes GS, Girardi DM, Bernardes JPG, et al.Clinical benefit and radiological response with BRAF inhibitor in a patient with recurrent ameloblastoma harboring V600E mutation[J]. BMC Cancer, 2018, 18(1): 887-892.
[4] Tan S, Pollack JR, Kaplan MJ, et al.BRAF inhibitor treatment of primary BRAF-mutant ameloblastoma with pathologic assessment of response[J]. Oral Surg Oral Med Oral Pathol Oral Radiol, 2016, 122(1): e5-e7.
[5] Derakhshan S, Aminishakib P, Karimi A, et al.High frequency of BRAF V600E mutation in Iranian population ameloblastomas[J]. Med Oral Patol Oral Cir Bucal, 2020, 25(4): e502-e507.
[6] Yang R, Liu Z, Gokavarapu S, et al.Recurrence and cancerization of ameloblastoma: multivariate analysis of 87 recurrent craniofacial ameloblastoma to assess risk factors associated with early recurrence and secondary ameloblastic carcinoma[J]. Chin J Cancer Res, 2017, 29(3): 189-195.
[7] Kelppe J, Thorén H, Ristimäki A, et al.BRAF V600E expression in ameloblastomas-a 36 patient cohort from Helsinki University Hospital[J]. Oral Dis, 2019, 25(4): 1169-1174.
[8] Seki-Soda M, Sano T, Ito K, et al.An immunohistochemical and genetic study of BRAF V600E mutation in Japanese patients with ameloblastoma[J]. Pathol Int, 2020, 70(4): 224-230.
[9] Pereira NB, Pereira KM, Coura BP, et al.BRAF V600E mutation in the diagnosis of unicystic ameloblastoma[J]. J Oral Pathol Med, 2016, 45(10): 780-785.
[10] Oh KY, Cho SD, Yoon HJ, et al.Discrepancy between immunohistochemistry and sequencing for BRAF V600E in odontogenic tumours: comparative analysis of two VE1 antibodies[J]. J Oral Pathol Med, 2021, 50(1): 85-91.
[11] Shirsat PM, Bansal S, Prasad P, et al.Low frequency of BRAF V600E immunoexpression in mandibular ameloblastomas: an institutional study[J]. J Oral Maxillofac Pathol, 2018, 22(3): 353-359.
[12] Fregnani ER, Perez DE, Paes de Almeida O, et al. BRAF-V600E expression correlates with ameloblastoma aggressiveness[J]. Histopathology, 2017, 70(3): 473-484.
[13] Sant'Ana MSP, Dos Santos Costa SF, da Silva MP, et al. BRAF p.V600E status in epithelial areas of ameloblastoma with different histological aspects: implications to the clinical practice[J]. J Oral Pathol Med, 2021, 50(5): 478-484.
[14] Zhang R, Yang Q, Qu J, et al.The BRAF p.V600E mutation is a common event in ameloblastomas but is absent in odontogenic keratocysts[J]. Oral Surg Oral Med Oral Pathol Oral Radiol, 2020, 129(3): 229-235.
[15] González-González R, López-Verdín S, Lavalle-Carrasco J, et al.Current concepts in ameloblastoma-targeted therapies in B-raf proto-oncogene serine/threonine kinase V600E mutation: systematic review[J]. World J Clin Oncol, 2020, 11(1): 31-42.